Perets, R., Sharma, M., Strickler, J. H., Golan, T., Hollebecque, A., Henner, W., … Harding, J. J. (2024). Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Perets, Ruth, Manish Sharma, John H. Strickler, Talia Golan, Antoine Hollebecque, William Henner, Athanasios Vasilopoulos, Gladys Morrison Thiele, Michael Charles Burns, and James J. Harding. “Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Perets R, Sharma M, Strickler JH, Golan T, Hollebecque A, Henner W, et al. Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Perets, Ruth, et al. “Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Perets R, Sharma M, Strickler JH, Golan T, Hollebecque A, Henner W, Vasilopoulos A, Thiele GM, Burns MC, Harding JJ. Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications. JOURNAL OF CLINICAL ONCOLOGY. 2024.